I posted as much this week, but what is the Aspire Capital raise for if not to fund trials? They gloated about their non-dilutive capital with Aspire, then raise 3 weeks later?
We have more than doubled here since December as I'm sure you know. I think being conservative is good, so you will be pleasantly surprised when we do it in two to three years. We should hit 40 by the end of this year. Good luck.
$25 million, 12,500M shares priced at $2.00. After the non-dilutive financing with Aspire Capital, what, a month ago or less? With their publicity they must have felt they wouldn't have a better time in the future to do this, so they do it now. OK, get on with it, their cash runway will be longer, let's see what they say now. I am in it to win, not giving my shares away. But this will hurt short term.
Better day today, IBB up, OSIR moving up, the next couple of months, and rest of the year should be great for us. We have nothing but good things happening here, and lot's of them.
What is your rationale, how does that add value, unless they couple it with news of a partnership? I can see it adding a nickel or so, but unless other news, I don't see it.
NeoStem Analysts at MLV & Co. initiated coverage on shares of NeoStem (NYSE:NBS) in a research report issued to clients and investors on Monday. The firm set a “buy” rating and a $14.00 price target on the stock. MLV & Co.’s price target indicates a potential upside of 416.61% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Oppenheimer initiated coverage on shares of NeoStem in a research note on Friday, January 9th. They set an “outperform” rating and a $10.00 price target on the stock. Separately, analysts at Aegis reiterated a “positive” rating and set a $21.00 price target on shares of NeoStem in a research note on Tuesday, January 6th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $18.17.
MLV and Co. Analyst Vernan Bernardino follows NeoStem. Here's an excerpt from his prior coverage of the company in 2013: Vernon Bernardino
We believe Progenitor Cell Therapy (PCT) has unique exposure to the cell product manufacturing landscape. PCT recorded $14MM in revenues in 2012 or 42.6% year-over-year (YOY) growth. This was partly driven by a change in accounting for revenue recognition implemented last year. As a result, we anticipate that 2013 cell therapy services revenues will only grow 8% YOY in 2013, as some revenue recognition was then shifted forward into 2012. As you point out, PCT stands to benefit from the advancement of its clients' clinical programs and contract needs. Therefore, we project cell therapy services revenue growth for PCT will re-accelerate to 50% annually, amounting for $27MM in 2014 and growing to $100MM by 2018.
By giving PCT revenues a 4-times multiple, this values NeoStem at $108MM alone - its current market cap value. We believe NeoStem stock is currently ascribed value from the company's contract cell products development and manufacturing services subsidiary only. We believe this value recognizes the company's initial strategy of acquiring PCT, which critically positioned the company at the forefront of several emerging technologies. We, of course, believe this valuation discounts any contribution from AMR-001, which represents near-term upside potential.
Another excerpt: Ganetespib (Synta Pharmaceuticals Corp., Lexington, MA, USA) is a new potent inhibitor of HSP90 with favorable pharmacologic and safety characteristics over the first generation of HSP90 inhibitor compounds [46,47]. Ganetespib is structurally distinct, relatively hydrophobic, and considerably smaller in size to the prototypical ansamycin class of HSP90 inhibitors. Ganetespib readily penetrates, distributes and is retained throughout solid tumors in in vivo models [37,47]. Ganetespib has shown preclinical activity against NSCLC models, including those driven by mutant EGFR, rearranged ALK, and/or mutant KRAS [6,48,49], and has been shown to potentiate the effect of taxanes and PI3K/mTOR inhibitor BEZ235 in NSCLC models [48,49]. In clinical trials, ganetespib monotherapy has a manageable side effect profile, as well as promising clinical activity in heavily pretreated patients with advanced NSCLCs, most notably in patients with tumors harboring ALK gene rearrangements .
It is reasonable to suggest that pharmacological blockade of HSP90 might produce multifaceted effects on various cell signaling pathways of cancer cells, including the inhibition prosurvival oncogenic signals in IR- and drug resistant cancers [51,52]. Studies have shown that ganetespib had a radiosensitizing effect in preclinical colorectal cancer model systems  but has not been explored in NSCLC. Here we examine the radiosensitizing effects of ganetespib on human lung AC cells with differing genetic backgrounds, including KRAS mutant A549 cells, EGFR mutant primary T2851 cells, and primary T2821 cells that express wild type (wt) KRAS and EGFR.
Agree, that's why we're here, this article is full of scientific documentation the drug works.
I'm one of the lucky ones, most of my shares were purchased recently, so averaged in at 2.57. This stock may not be getting respect now, but this is how money is made in the market, to buy good stocks on sale, when irrationality prevails.
Except from conclusion...
Ganetespib was also shown to: Inhibit cell growth and migration, tumor sphere formation induced apoptosis and cell cycle redistribution, led to irreversible cell growth arrest and the development of the senescence phenotype in lung adenocarcinoma cells. The most clinically significant finding of this study is our demonstration that treatment with ganetespib has the capacity to significantly improve the efficacy of IR therapy in primary human lung adenocarcinoma T2821 xenografts.
Sentiment: Strong Buy
Nice to see a post. Nice to see a post from somebody with a credible message. I agree technically, just want to see some demand for this stock, volume! What do we have going on? Management is so quiet lately! Maybe we're in a quiet period, pending a major development? Love their trachea product, imagine doing that with other thoracic organs, and extending that to cardiac repair applications! The future is here, they just need solid backing, partnership!
Reposting lest we forget...
Besides the 18 million grant...
by ericskiba242 • May 22, 2015 11:23 AM
That has funded this phase 3 trial....lets not forget about Japan partnership....deal with invetech, PCT generating revenue.....the list goes on
There are a few of us here in AVXL, quite a good week we had last week, going to be huge as their trial data is further released.
Please this coming October 10th follow along with your new list. These gains are way outstanding! And ATRS is still stuck in the $2's, hopefully not for long, from what I read here, it is ready to fly like an eagle, would like to see it above $3 soon. Thanks for your continued posts here Andre!